A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS

被引：4
|
作者：
DiNardo, Courtney D.
Kantarjian, Hagop M.
Ravandi, Farhad
Konopleva, Marina
Kadia, Tapan M.
Borthakur, Gautam
Daver, Naval G.
Durand, Mends
Rivera, Silvia
Quintas-Cardama, Alfonso
Garcia-Manero, Guillermo
Cortes, Jorge E.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.2698.2698
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2698
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias
    Jain, Nitin
    Cortes, Jorge E.
    Estrov, Zeev
    Borthakur, Gautam
    Dong, Xiao Q.
    Kumar, Veeral J.
    Kantarjian, Hagop M.
    BLOOD, 2013, 122 (21)
  • [22] A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    DiNardo, Courtney D.
    Olin, Rebecca
    Ishizawa, Jo
    Sumi, Hiroyuki
    Xie, Jingdong
    Kato, Kazunobu
    Kumar, Prasanna
    Andreeff, Michael
    BLOOD, 2019, 134
  • [23] Clonal evolution in high-risk MDS and secondary AML treated with venetoclax and azacitidine
    Koch, R.
    Ganster, C.
    Dierks, S.
    Shirneshan, K.
    Rittscher, K.
    Nothnick, G.
    Becker, S.
    Shumilov, E.
    Haase, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 199 - 199
  • [24] Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS
    Savona, Michael R.
    Pollyea, Daniel A.
    Stock, Wendy
    Oehler, Vivian G.
    Schroeder, Mark A.
    Lancet, Jeffrey
    McCloskey, James
    Kantarjian, Hagop M.
    Ma, Weidong Wendy
    Shaik, Naveed
    Laird, A. Douglas
    Zeremski, Mirjana
    O'Connell, Ashleigh
    Chan, Geoffrey
    Cortes, Jorge E.
    CLINICAL CANCER RESEARCH, 2018, 24 (10) : 2294 - 2303
  • [25] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan
    DiNardo, Courtney
    Jain, Nitin
    Borthakur, Gautum
    Cortes, Jorge
    Adam, Craig
    Ravandi, Farhad
    CANCER RESEARCH, 2014, 74 (19)
  • [26] Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML).
    Garcia-Manero, Guillermo
    Yang, Allen S.
    Giles, Francis
    Faderl, Stefan
    Ravandi, Farhad
    Cortes, Jorge
    Newsome, Willie M.
    Issa, Jean-Pierre
    Patterson, Tracy-Ann
    Dubay, Marja
    Li, Zuomei
    Kantarjian, Hagop
    Martell, Robert E.
    BLOOD, 2006, 108 (11) : 552A - 553A
  • [27] RESULTS FROM PHASE I/II STUDY OF THE COMBINATION OF ORAL RIGOSERTIB AND AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    Navada, S.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Alvarado, Y.
    Daver, N.
    DiNardo, C.
    Konopleva, M.
    Borthakur, G.
    Fenaux, P.
    Fruchtman, S.
    Zbyszewski, P.
    Silverman, L.
    HAEMATOLOGICA, 2016, 101 : 74 - 74
  • [28] A Phase II Study of Twice Daily Cytarabine and Fludarabine and Gentuzumab Ozogamycin (GO) In Patients (pts) with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Ghanem, Hady Antoine
    Ravandi, Farhad
    Faderl, Stefan
    Cortes, Jorge
    Reyes, Ardes S.
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan A.
    Konopleva, Marina
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 903 - 903
  • [29] Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes
    Borthakur, Gautam
    Huang, Xuelin
    Kantarjian, Hagop
    Faderl, Stefan
    Ravandi, Farhad
    Ferrajoli, Alessandra
    Torma, Ritva
    Morris, Gail
    Berry, Donald
    Issa, Jean-Pierre
    LEUKEMIA & LYMPHOMA, 2010, 51 (01) : 73 - 78
  • [30] Sequential Azacitidine and High-Dose Lenalidomide for Relapsed and Refractory High-Risk MDS and AML: Interim Analysis of a Phase 2 Study
    Pollyea, Daniel A.
    Smith, Clayton A.
    Nguyen, Vu H.
    Fullerton, Aaron
    Schatz, Derek
    Bedrick, Edward J.
    Gutman, Jonathan A.
    BLOOD, 2014, 124 (21)
12345